Skip to main content

Table 4 Total life years and life years by health state

From: A disease progression model estimating the benefit of tolvaptan on time to end-stage renal disease for patients with rapidly progressing autosomal dominant polycystic kidney disease

 

Tolvaptan

No Tolvaptan

Differencea

Life yearsa

27.4

26.6

0.7

 CKD stage G1

1.3

1.0

0.4

 CKD stage G2

4.9

3.9

1.0

 CKD stage G3

7.3

5.9

1.5

 CKD stage G4

3.2

2.9

0.3

 ESRD

10.6

13.0

−2.4

  1. CKD Chronic kidney disease, ESRD End-stage renal disease
  2. aDiscrepancies in life years and differences are due to rounding